High biologics demand spurs need for greater contract manufacturing
Pharmaceutical Technology
APRIL 24, 2023
Biologics are costly to produce and sell, and the more recent modalities, such as cell and gene therapies, can be difficult to manufacture. With new drugs on the market, companies are now looking for ways to manufacture recently approved biologics, and countries are racing to claim their corner – or maintain their decades-old market share.
Let's personalize your content